Skip to content
★ Sign in to follow
DG

David Gearing

Executive
Nexvet Biopharma plc
Total declarations
11
Company
1
▲ Purchases (4 ops.)
€128k
▼ Sales (0 ops.)
—

Latest filing published 09 Nov 2016 for Nexvet Biopharma plc, €1,044.

Insider track record

Disclosed buys
4
Disclosed sells
0
Signal history

Closed purchases

Market purchases
4

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

David Gearing: trading record in brief

David Gearing discloses dealings in Nexvet Biopharma plc to SEC (Form 4). The record holds 11 filings, for trades running from 8 June 2015 to 1 July 2016.

No open-market sale appears; the market trades are 4 purchases worth €128k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant and 6 option exercises. 2016 to date brings 4 purchases and no sales.

The median purchase comes to €32k. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 9 November 2016, reports an option exercise of €1,044 in Nexvet Biopharma plc. The last purchase on record was published on 7 March 2016, which is 3,899 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to David Gearing

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations11 total
  • ◇
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    1,150 USD0SEC
    9,203 shares@ US$0.125Ordinary SharesSEC:0001572426-16-000240:0
  • ◇
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    467 USD17SEC
    3,733 shares@ US$0.1250.3% of flowOrdinary SharesSEC:0001572426-16-000190:0
  • ◇
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    938 USD17SEC
    7,500 shares@ US$0.1250.7% of flowOrdinary SharesSEC:0001572426-16-000190:1
  • ▲
    CHIEF SCIENTIFIC OFFICERExecutivesNexvet Biopharma plc
    6,888 USD33SEC
    2,113 shares@ US$3.264.9% of flowOrdinary SharesSEC:0001171000-16-000116:0
    Canonical exit: 1 Jun 2016 (T+90)
  • ▲
    CHIEF SCIENTIFIC OFFICERExecutivesNexvet Biopharma plc
    30,150 USD37SEC
    9,000 shares@ US$3.3521.4% of flowOrdinary SharesSEC:0001171000-16-000116:1
    Canonical exit: 2 Jun 2016 (T+90)
  • ▲
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    62,700 USD33SEC
    19,000 shares@ US$3.3044.2% of flowOrdinary SharesSEC:0001572426-16-000162:0
    Canonical exit: 25 May 2016 (T+90)
  • ▲
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    40,501 USD34SEC
    12,126 shares@ US$3.3428.5% of flowOrdinary SharesSEC:0001572426-16-000162:1
    Canonical exit: 26 May 2016 (T+90)
  • ◇
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    700 USD0SEC
    5,600 shares@ US$0.125Ordinary SharesSEC:0001171000-15-000110:0
  • ◇
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    1,151 USD0SEC
    9,204 shares@ US$0.125Ordinary SharesSEC:0001572426-15-000123:0
  • ◇
    CHIEF SCIENTIFIC OFFICERExecutivesNexvet Biopharma plc
    467 USD0SEC
    3,734 shares@ US$0.125Ordinary SharesSEC:0001171000-15-000047:0
  • ◆
    Chief Scientific OfficerExecutivesNexvet Biopharma plc
    700 USD0SEC
    5,600 shares@ US$0.125Ordinary SharesSEC:0001171000-15-000015:0

11 of 11 declarations